Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature

Eleonoor A. R. Theunissen; Sophie C. J. Bosma; Charlotte L. Zuur; René Spijker; Sieberen van der Baan; Wouter A. Dreschler; Jan Paul de Boer; Alfons J. M. Balm; Coen R. N. Rasch

doi:10.1002/hed.23551

Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature

Eleonoor A. R. Theunissen, Sophie C. J. Bosma, Charlotte L. Zuur, René Spijker, Sieberen van der Baan, Wouter A. Dreschler, Jan Paul de Boer, Alfons J. M. Balm, Coen R. N. Rasch

Research output: Contribution to journal › Review article › Academic › peer-review

71 Citations (Scopus)

Abstract

Both radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT. Comprehensive search of Medline and Embase with the terms "radiotherapy" combined with "ototoxicity," "head and neck squamous cell carcinoma," and synonyms. Of the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose. The wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance

Original language	English
Pages (from-to)	281-292
Journal	Head & neck
Volume	37
Issue number	2
DOIs	https://doi.org/10.1002/hed.23551
Publication status	Published - 2015

Access to Document

10.1002/hed.23551

Cite this

@article{83712ed5f484433ca42f96645b4f70f3,

title = "Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature",

abstract = "Both radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT. Comprehensive search of Medline and Embase with the terms {"}radiotherapy{"} combined with {"}ototoxicity,{"} {"}head and neck squamous cell carcinoma,{"} and synonyms. Of the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose. The wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance",

author = "Theunissen, {Eleonoor A. R.} and Bosma, {Sophie C. J.} and Zuur, {Charlotte L.} and Ren{\'e} Spijker and {van der Baan}, Sieberen and Dreschler, {Wouter A.} and {de Boer}, {Jan Paul} and Balm, {Alfons J. M.} and Rasch, {Coen R. N.}",

year = "2015",

doi = "10.1002/hed.23551",

language = "English",

volume = "37",

pages = "281--292",

journal = "Head & neck",

issn = "1043-3074",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature

AU - Theunissen, Eleonoor A. R.

AU - Bosma, Sophie C. J.

AU - Zuur, Charlotte L.

AU - Spijker, René

AU - van der Baan, Sieberen

AU - Dreschler, Wouter A.

AU - de Boer, Jan Paul

AU - Balm, Alfons J. M.

AU - Rasch, Coen R. N.

PY - 2015

Y1 - 2015

N2 - Both radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT. Comprehensive search of Medline and Embase with the terms "radiotherapy" combined with "ototoxicity," "head and neck squamous cell carcinoma," and synonyms. Of the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose. The wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance

AB - Both radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT. Comprehensive search of Medline and Embase with the terms "radiotherapy" combined with "ototoxicity," "head and neck squamous cell carcinoma," and synonyms. Of the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose. The wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance

U2 - 10.1002/hed.23551

DO - 10.1002/hed.23551

M3 - Review article

C2 - 24478269

SN - 1043-3074

VL - 37

SP - 281

EP - 292

JO - Head & neck

JF - Head & neck

IS - 2

ER -